<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20052">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01962311</url>
  </required_header>
  <id_info>
    <org_study_id>PHRN11-CA-METABALS</org_study_id>
    <secondary_id>2012-A00145-38</secondary_id>
    <nct_id>NCT01962311</nct_id>
  </id_info>
  <brief_title>Evaluation of Metabolomic Analysis in Early Diagnosis of ALS</brief_title>
  <acronym>METABALS</acronym>
  <official_title>Evaluation of Metabolomic Analysis in Early Diagnosis of ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is expected to answer the question of interest assays of metabolites in the CSF
      as a tool for early diagnosis and should show whether it is possible or not to use such
      markers in the blood or urine. These studies should also help shed light on the
      pathophysiological original early clinical disease. While ALS appears to be more a clinical
      syndrome that pathophysiological entity unique metabolic abnormalities identified could help
      identify mechanisms disrupted in which therapeutic interventions will be possible.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A blood test that would allow the diagnosis

        1. to reduce the time between the first signs and diagnosis in ALS patients for
           therapeutic treatment earlier and

        2. to exclude rapidly non ALS in their avoiding unnecessary investigations and anxiety of
           being infected with a terrible prognosis disease. It is currently accepted that
           neurodegenerative diseases such as ALS begin before the first clinical signs and the
           patient could benefit from a more efficient care if it was early.

      Conduct a prospective study with 400 patients.

      The secondary objectives are:

        1. attempt to improve the predictive power of markers assays by adding new parameters

        2. to check whether the assayed molecules in other environments more accessible (blood,
           urine) would provide equivalent diagnostic power of those assayed in the CSF

        3. identify metabolic pathways disrupted early that could be related to the pathogenesis
           of neurodegeneration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Diagnostic markers studied are metabolites of cerebrospinal fluid, blood and urine measured by three complementary analytical methods</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>diagnostic criteria Diagnostic markers studied are metabolites of cerebrospinal fluid, blood and urine measured by three complementary analytical methods: GC / MS, LC / MSMS and proton NMR spectroscopy. These metabolites, the number of one hundred, can be grouped into four main groups: molecules of metabolism of carbohydrates, lipids, proteins, steroids</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>ALS</condition>
  <arm_group>
    <arm_group_label>All patients</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>lumbar puncture</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lumbar puncture</intervention_name>
    <description>lumbar puncture at enrollment in study</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 30-80

          -  Consent signed

          -  affiliation to a social security organism

        Exclusion Criteria:

          -  Patients treated with RILUZOLE

          -  Enrollment in an other study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian ANDRES, MD-PHD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital TOURS and INSERM U930</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian ANDRES, MD-PHD</last_name>
    <phone>+33(0)2 47 47 80 54</phone>
    <email>andres@med.univ-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wiebe de JONG</last_name>
    <phone>+33(0)2 47 47 46 80</phone>
    <email>w.de-jong@univ-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pôle Neurosciences et Spécialités ,Service de Neurologie,CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien CASSEREAU, MD-PHD</last_name>
      <phone>+33241353831</phone>
      <email>jucassereau@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Julien CASSEREAU, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique MAUGIN, MD-PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vivien PAUTOT, MD-PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie et Pathologie du Mouvement Clinique de Neurologie, Pôle des Neurosciences et de l'Appareil Locomoteur INSERM U 837</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique DANEL, MD-PHD</last_name>
      <phone>+33320446752</phone>
      <email>veronique.danel@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Alain DESTEE, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique DANEL, MD-PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline MOREAU, MD-PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David DEVOS, MD-PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc DEFEBVRE, MD-PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie et Centre SLA, CHU de Limoges, EA3174 Université de Limoges - Faculté de médecine</name>
      <address>
        <city>Limoges</city>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe COURATIER, MD-PHD</last_name>
      <phone>+33555056561</phone>
      <email>philippe.couratier@unilim.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe COURATIER, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre SLA, CHU Gui de Chauliac, Université de Montpellier 1</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William CAMU, MD-PHD</last_name>
      <phone>+33467330281</phone>
      <email>w-camu@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>William CAMU, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche de l'Institut du Cerveau et de la moëlle UPMC Paris 6,Département des Maladies du Système Nerveux</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-François PRADAT, MD-PHD</last_name>
      <phone>+330142162471</phone>
      <email>pierre-francois.pradat@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-François PRADAT, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucette LACOMBLEZ, MD-PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François SALACHAS, MD-PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaëlle BRUNETEAU, MD-PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadine LEFORESTIER, MD-PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothée LENGLET, MD-PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de neurologie, CHU La Milétrie, POITIERS, Faculté de Médecine</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Philippe NEAU, MD-PHD</last_name>
      <email>jean-philippe.neau@chu-poitiers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Adrien JULIAN, MD-PHD</last_name>
      <phone>+33638930503</phone>
      <email>adr.julian@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-Philippe NEAU, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adrien JULIAN, :MD-PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU -TOURS-Service de Neurologie</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe CORCIA, MD-PHD</last_name>
      <phone>+330247473724</phone>
      <email>corcia@med.univ-tours.fr</email>
    </contact>
    <contact_backup>
      <last_name>Wiebe de JONG</last_name>
      <phone>+33247474680</phone>
      <email>w.de-jong@univ-tours.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Julien PRALINE, Md-PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe CORCIA, MD-PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>January 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Spinal Cerebrospinal Fluid</keyword>
  <keyword>Urine</keyword>
  <keyword>SERUM</keyword>
  <keyword>Diagnosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
